About Me

My mother was murdered by what I call corporate and political homicide i.e. FOR PROFIT! she died from a rare phenotype of CJD i.e. the Heidenhain Variant of Creutzfeldt Jakob Disease i.e. sporadic, simply meaning from unknown route and source. I have simply been trying to validate her death DOD 12/14/97 with the truth. There is a route, and there is a source. There are many here in the USA. WE must make CJD and all human TSE, of all age groups 'reportable' Nationally and Internationally, with a written CJD questionnaire asking real questions pertaining to route and source of this agent. Friendly fire has the potential to play a huge role in the continued transmission of this agent via the medical, dental, and surgical arena. We must not flounder any longer. ...TSS

Thursday, September 18, 2014

New Executive Actions to
Combat Antibiotic Resistance and Protect Public Health

Lisa Monaco, Dr. John P. HoldrenSeptember 18, 2014
02:33 PM EDT

Today, the Obama
administration is announcing a comprehensive set of new federal actions to
combat the rise of antibiotic-resistant bacteria and protect public health.
Additionally, the President’s Council of Advisors on Science and Technology
(PCAST) is releasing a related report on Combating Antibiotic Resistance.

The discovery of antibiotics in the early
20th century fundamentally transformed medicine; antibiotics now save millions
of lives each year in the United States and around the world. Yet bacteria
repeatedly exposed to the same antibiotics can become resistant to even the most
potent drugs. These so-called antibiotic-resistant bacteria can present a
serious threat to public health, national security, and the economy.In fact, according to the Centers for Disease
Control and Prevention, antibiotic-resistant infections are associated with an
additional 23,000 deaths and 2 million illnesses in the United States each year.
The estimated annual impact of antibiotic-resistant infections on the national
economy is $20 billion in excess direct health care costs, and as much as $35
billion in lost productivity from hospitalizations and sick days. Antibiotics
are also critical to many modern medical interventions, including chemotherapy,
surgery, dialysis, and organ transplantation.The Administration is ramping up our efforts to
combat antibiotic-resistant bacteria through a series of new actions
including:

An Executive Order directing the federal government to work domestically
and internationally to reduce the emergence and spread of antibiotic-resistant
bacteria and to help ensure the continued availability of effective treatments
for bacterial infections. The Executive Order establishes a new interagency Task
Force and Federal Advisory Council and includes calls for better monitoring of
resistant infections, improved regulations governing antibiotic use, more robust
research to develop new and effective methods for combating antibiotic
resistance, and increased international cooperation to curb the global rise in
resistant bacteria. Importantly, the Executive Order directs the new interagency
Task Force to develop a five-year National Action Plan for implementing both the
National Strategy for Combating Antibiotic-Resistant Bacteria, which
includes goals, milestones, and assessment metrics for detecting, preventing,
and controlling antibiotic-resistant bacteria, and to address the new PCAST
report.

A National Strategy for Combating
Antibiotic-Resistant Bacteria, which articulates national goals, priorities, and
specific objectives that provide an overarching framework for federal
investments aimed at combating antibiotic resistance. These include: preventing
the spread of resistant bacteria; strengthening national efforts to identify
instances of antibiotic resistance; working to develop new antibiotics,
therapies, and vaccines; and improving international collaboration on this
issue.

A new PCAST report entitled Combating Antibiotic
Resistance, containing
recommendations that were developed by PCAST in consultation with a diverse
group of experts that span the human and veterinary sectors for actions that the
federal government can take to strengthen the nation’s ability to combat
antibiotic-resistant bacteria.

The launch of a $20 million
prize sponsored by the National Institutes of Health, Biomedical
Advanced Research and Development Authority, and the Food and Drug
Administration to facilitate the development of a rapid diagnostic test to be
used by health care providers to identify highly resistant bacterial infections
at the point of patient care.

These actions will help the nation contain the
spread of resistant bacterial strains, manage existing antibiotics to prevent
the development of new resistant strains, and help guarantee a steady pipeline
of new, effective antibiotics and diagnostics. Most importantly, these actions
will help save thousands of lives each year.Learn more:

Lisa Monaco is Assistant to
the President for Homeland Security & Counterterrorism. Dr. John P. Holdren
is Assistant to the President for Science and Technology and Director of the
White House Office of Science and Technology Policy.